BACKGROUND: The purpose of the current study was to determine the degree to which milk-borne insulin-like growth factor-I (IGF-I) is absorbed. METHODS: Cesarean-derived piglets were fitted with umbilical arterial and venous catheters within 2 h of birth and were administered formula containing 21.7 +/- 1.8 microCi of iodinated recombinant human IGF-1 (125I-rhIGF-I) by orgogastric gavage. Blood samples were taken before administration of the 125I-rhIGF-I (t0) and for 4 h postgavage. Plasma was obtained by centrifugation and total and trichloroacetic acid precipitable radioactivity were determined. Immunoreactive 125I-rhIGF-I was assessed using a polyclonal antibody to human IGF-I. Four hours after feeding, intestines were removed, divided into 13 segments, and flushed with saline. Radioactivity within the small intestinal lumen and wall were measured. RESULTS: Radioactivity in portal blood was higher than t0 at all times points (p < 0.05), whereas arterial radioactivity did not differ from t0 until 30 min postgavage. On average 18-20% of total radioactivity in both portal and arterial blood was acid-precipitable, with the proportion decreasing over time (p < 0.001). Immunoprecipitable radioactivity averaged 3-5% of the total radioactivity and was higher in portal than arterial blood (p < 0.05). Based on a plasma volume of 0.062 +/- 0.005 L and a baseline plasma IGF-I concentration of 1.81 +/- 0.56 nmol/L, absorbed 125I-rhIGF-I represented 0.205% of the total plasma IFG-I pool, whereas 14% of the dose was associated with the lining of the intestine. CONCLUSIONS: Absorption of orally administered IGF-I does not contribute significantly to circulating IGF-I.
BACKGROUND: The purpose of the current study was to determine the degree to which milk-borne insulin-like growth factor-I (IGF-I) is absorbed. METHODS: Cesarean-derived piglets were fitted with umbilical arterial and venous catheters within 2 h of birth and were administered formula containing 21.7 +/- 1.8 microCi of iodinated recombinant humanIGF-1 (125I-rhIGF-I) by orgogastric gavage. Blood samples were taken before administration of the 125I-rhIGF-I (t0) and for 4 h postgavage. Plasma was obtained by centrifugation and total and trichloroacetic acid precipitable radioactivity were determined. Immunoreactive 125I-rhIGF-I was assessed using a polyclonal antibody to humanIGF-I. Four hours after feeding, intestines were removed, divided into 13 segments, and flushed with saline. Radioactivity within the small intestinal lumen and wall were measured. RESULTS: Radioactivity in portal blood was higher than t0 at all times points (p < 0.05), whereas arterial radioactivity did not differ from t0 until 30 min postgavage. On average 18-20% of total radioactivity in both portal and arterial blood was acid-precipitable, with the proportion decreasing over time (p < 0.001). Immunoprecipitable radioactivity averaged 3-5% of the total radioactivity and was higher in portal than arterial blood (p < 0.05). Based on a plasma volume of 0.062 +/- 0.005 L and a baseline plasma IGF-I concentration of 1.81 +/- 0.56 nmol/L, absorbed 125I-rhIGF-I represented 0.205% of the total plasma IFG-I pool, whereas 14% of the dose was associated with the lining of the intestine. CONCLUSIONS: Absorption of orally administered IGF-I does not contribute significantly to circulating IGF-I.
Authors: Marcia H Monaco; Derek E Gronlund; Gregory T Bleck; Walter L Hurley; Matthew B Wheeler; Sharon M Donovan Journal: Transgenic Res Date: 2005-10 Impact factor: 2.788
Authors: Elizabeth A Reznikov; Sarah S Comstock; Jennifer L Hoeflinger; Mei Wang; Michael J Miller; Sharon M Donovan Journal: Curr Dev Nutr Date: 2017-12-26
Authors: W Liermann; C T Schäff; J Gruse; M Derno; J M Weitzel; E Kanitz; W Otten; A Hoeflich; T Stefaniak; H Sauerwein; R M Bruckmaier; J J Gross; H M Hammon Journal: J Dairy Sci Date: 2020-02-20 Impact factor: 4.034